Taisho Pharmaceutical has a product lineup centered on treatments in the fields of infectious diseases, iorthopedic disorders, and metabolic diseases
New Drug Research and Development
Taisho Pharmaceutical, which is advancing R&D for new drugs, has designated infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases as its priority fields R&D. By concentrating business resources in those priority fields, Taisho Pharmaceutical is working to quickly launch new products. In parallel, the company is striving to expand its new drug pipeline by promoting in-licensing of promising compounds from and joint R&D initiatives with companies and research institutions in Japan and overseas.
See Taisho Pharmaceutical Holdings’s “Development Status of Prescription Pharmaceuticals”